Explanipedia

808 | PHASE 1b/2 STUDY OF MAPLIRPACEPT (PF‐07901801), TAFASITAMAB, AND LENALIDOMIDE IN TRANSPLANT‐INELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA PARTICIPANTS Open

Adam J. Olszewski, Koichi Aizawa, Yasmin Karimi, Dahlia Sano, Sung Yong Oh , et al. · 2025

A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment Open

Victor T. G. Lin, Esprit Ma, Neha Jain, Zhiyu Xia, Danny Sheinson , et al. · 2025

Background Next-generation sequencing (NGS) testing in patients with metastatic non-small cell lung cancer (mNSCLC) identifies actionable driver oncogenes (ADO) and targeted treatment (TT). Potential inequities were evaluated in NGS testin…

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes Open

Thomas Stricker, Neha Jain, Esprit Ma, Elaine Yu, Rongrong Wang , et al. · 2024

Background A recent real-world study observed that 24% of patients with advanced non–small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADOs) initiated nontargeted therapies before biomarker test results became available. Th…

Hedgehog signaling enables repair of ribosomal DNA double-strand breaks Open

Tshering Lama-Sherpa, Victor T. G. Lin, Brandon J. Metge, Shannon E. Weeks, Dongquan Chen , et al. · 2020

Ribosomal DNA (rDNA) consists of highly repeated sequences that are prone to incurring damage. Delays or failure of rDNA double-strand break (DSB) repair are deleterious, and can lead to rDNA transcriptional arrest, chromosomal translocati…

Abstract 3740: Ionizing radiation-induced transcriptomic changes in triple-negative breast cancer cells reveal putative mechanisms of treatment resistance Open

Victor T. G. Lin, Tshering Lama-Sherpa, Rajeev S. Samant, Lalita A. Shevde · 2019

Breast cancer is the most common malignancy and the second leading cause of cancer-associated deaths in women. Of these, triple-negative breast cancers (TNBCs) remain the most difficult to treat. Unlike hormone-driven breast cancers, TNBCs…

The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology Open

Victor T. G. Lin, Eddy S. Yang · 2019

The treatment of cancer continues to evolve toward personalized therapies based on individual patient and tumor characteristics. Our successes and failures in adopting a precision-oncology approach have demonstrated the utmost importance i…

First-Line Treatment of Widely Metastatic <i>BRAF</i>-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition Open

Victor T. G. Lin, Lisle M. Nabell, Sharon A. Spencer, William R. Carroll, Shuko Harada , et al. · 2018

Salivary duct carcinoma (SDC) is a rare and aggressive malignancy for which limited data exist to guide treatment decisions. With the advent of advanced molecular testing and tumor genomic profiling, clinicians now have the ability to iden…

Significantly mutated genes and regulatory pathways in SCLC—a meta-analysis Open

Varsha Sundaresan, Victor T. G. Lin, Faming Liang, Frederic J. Kaye, Reika Kawabata‐Iwakawa , et al. · 2017

Developing Cures: Targeting Ontogenesis in Cancer Open

Victor T. G. Lin, Hawley C. Pruitt, Rajeev S. Samant, Lalita A. Shevde · 2017

TRIP6 antagonizes the recruitment of A20 and CYLD to TRAF6 to promote the LPA2 receptor-mediated TRAF6 activation Open

Fang‐Tsyr Lin, Vivian Lin, Victor T. G. Lin, Weei-Chin Lin · 2016

Victor T. G. Lin YOU? Author Swipe